Hey Owl vs FoxI missed your re-post on my thread. Yes converting...

Hey Owl vs Fox

I missed your re-post on my thread. Yes converting options is good move but this can easily go higher >$1.0 post mid-March result but I wouldn't be selling anytime soon as I'm counting high efficacy (80%) on clinical trial but this will also back-test eGFR result (of course it is double blinded which may not be available to us).

The China NMPA has already endorsed trial for ACTION-3 phase 2 (refer to last announcement-Clinical sites on mainland China are intended for Part 2 of the FSGS ACTION3 Phase 3 clinical trial currently recruiting in 11 other countries). The post mid-march result (I'm guessing end or March or early April) is pivotal in the sense that DXB will potentially receive additional payment from Advanz to secure commercialisation of DXB 200 and almost certain to get 2 additional commercial deals from China and US. This will also entail

• No Capital raise requirement to complete Phase 2 and 3 of ACTION-3
• Much better commercial deals in US and China compared to Advanz
• R & D payment reimbursement
• SP appreciation of many folds

DXB investment could be life changing as it is targeting Billion Dollar Market with no alternative medication available atm, but DYOR before any buy or sell and trust your investment. I'm not financial advisor.